Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 3/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13752779 | 0.84 | MEN1 (0.45) | OPRD1OPRK1CYP2C19CCR5 | |
| SCHEMBL14117673 | 0.79 | BCHE (0.41) | ALDH1A1 | |
| SCHEMBL27078006 | 0.79 | USP30 (0.36) | USP2CCR5 | |
| SCHEMBL12082089 | 0.77 | KLK7 (0.38) | ALDH1A1ACHE | |
| SCHEMBL2800249 | 0.77 | KLK7 (0.38) | ALDH1A1ACHE | |
| SCHEMBL12081802 | 0.77 | KLK7 (0.38) | ALDH1A1ACHE | |
| SCHEMBL12084970 | 0.77 | GRIN2B (0.42) | USP2CHRM2CHRM3 | |
| SCHEMBL18132258 | 0.77 | PARP1 (0.42) | CYP2C19 | |
| SCHEMBL14117683 | 0.77 | BCHE (0.39) | — | |
| SCHEMBL13744172 | 0.76 | GRIN2B (0.41) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | WYETH (US) | 2010-03-11 | — | — | US | claimed |
| WO-2005090316-A1 | HYDANTOINS HAVING RNase MODULATORY ACTIVITY | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | WYETH (US) | 2005-09-15 | — | — | US | claimed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2005090316-A1 | HYDANTOINS HAVING RNase MODULATORY ACTIVITY | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | WYETH (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | RNASEH1, RNASE1, RNASEL | NPFFR1 4492/4885NPFFR2 4752/4885CYP2D6 2129/4885 |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | NPFFR1 275/4885NPFFR2 365/4885CYP2D6 4593/4885 |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | RNASEH1, RNASE1, RNASEL | NPFFR1 4492/4885NPFFR2 4752/4885CYP2D6 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.